Plain-English translation of NCT06084897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying whether patients with advanced esophageal cancer who are responding well to a combination of chemotherapy and a (an immunotherapy medication that helps your immune system fight cancer) can benefit from adding radiation therapy to their treatment. The study will compare two approaches: giving radiation therapy right after chemotherapy and immunotherapy finish, or saving radiation therapy for later if the cancer starts growing again. Researchers will also study blood and tissue samples to better understand who benefits most from this treatment approach.
While chemotherapy and immunotherapy together have improved survival for patients with advanced esophageal cancer, doctors want to know if adding radiation therapy to the cancer's original location can help patients live longer and control their disease better. Current evidence from other cancer types suggests this approach might work, but we need solid proof before recommending it to all patients.
You likely qualify if…
You likely don't qualify if…
You will first complete 2 to 4 cycles of chemotherapy combined with immunotherapy. If your cancer responds well to this treatment, you will be randomly assigned to one of two groups: one group will receive radiation therapy right away as a consolidation treatment, while the other group will receive radiation therapy only if their cancer starts growing again. Throughout the study, you will have regular visits for physical exams, blood tests, and imaging scans to monitor your response to treatment. The trial will also collect tissue, blood, and urine samples for research to help doctors understand which patients benefit most from this combined approach.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China